和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00013 和黄医药

未开盘 01-09 16:08:35

23.240

+0.000

0.00%

最高23.440	最低22.860	成交量425.01万
今开23.320	昨收23.240	日振幅2.50%
总市值202.65亿	流通市值202.65亿	总股本8.72亿
成交额9,850万	换手率0.49%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00013","market":"HK","secType":"STK","nameCN":"和黄医药","latestPrice":23.24,"timestamp":1767946115002,"preClose":23.24,"halted":0,"volume":4250084,"delay":0,"floatShares":872000000,"shares":872000000,"eps":0.3438279496133699,"marketStatus":"未开盘","change":0,"latestTime":"01-09 16:08:35","open":23.32,"high":23.44,"low":22.86,"amount":98497558,"amplitude":0.024957,"askPrice":23.26,"askSize":40000,"bidPrice":23.24,"bidSize":7500,"shortable":3,"etf":0,"ttmEps":4.130105699675728,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":0,"adr":0,"listingDate":1624982400000,"exchange":"SEHK","adjPreClose":23.24,"openAndCloseTimeList":[[1767922200000,1767931200000],[1767934800000,1767945600000]],"volumeRatio":0.5574339323328521,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00013","defaultTab":"news","newsList":[{"id":"2602207113","title":"多重利好刺激股价走出“五连阳”，“躲过牛市”的和黄医药(00013)迎来反转时刻？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602207113","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602207113?lang=zh_cn&edition=full","pubTime":"2026-01-09 19:41","pubTimestamp":1767958896,"startTime":"0","endTime":"0","summary":"相较之下，作为一家手握3款商业化创新药并拥有首创抗体靶向偶联药物的创新药企，和黄医药却最终以8.56%的年度跌幅收场，显著跑输指数。去年8月7日美股盘前，和黄医药公布了其2025年中报业绩。最新数据显示，和黄医药的港股通持股比例已达27.28%。这便是和黄医药在25H2期内股价最大回撤幅度高达35.12%的重要原因之一。根据此前II期研究结果，索乐匹尼布针对wAIHA的整体应答率为66.7%，并展现出良好的安全性特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391129.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1588","BK4588","BK1191","00013","HCM","BK4585","BK4531","BK4007"],"gpt_icon":0},{"id":"2602300531","title":"和黄医药01月09日主力净流入1088.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2602300531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602300531?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:15","pubTimestamp":1767946544,"startTime":"0","endTime":"0","summary":"01月09日，和黄医药股价收平报23.24元，成交金额9849.8万元，换手率0.49%，振幅2.50%，量比0.56。和黄医药今日主力资金净流入1088.6万元，上一交易日主力净流出406.9万元。该股近5个交易日上涨10.79%，主力资金累计净流入1541.2万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入1086.8万元，其中净流入天数为9日。该股主力净额占比0.05%，港股市场排名153/2716。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162058a706694b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109162058a706694b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1588","00013","BK1191"],"gpt_icon":0},{"id":"2602310688","title":"和黄医药宣布“索乐匹尼布”3期研究获阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2602310688","media":"药渡","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602310688?lang=zh_cn&edition=full","pubTime":"2026-01-09 07:32","pubTimestamp":1767915148,"startTime":"0","endTime":"0","summary":"1月7日，和黄医药宣布，新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血成人患者的ESLIM-02研究的3期注册阶段已达到第5至24周治疗期间持久血红蛋白应答这一主要终点。索乐匹尼布治疗原发免疫性血小板减少症的ESLIM-01中国3期研究的积极结果已于《柳叶刀血液病学 》发表。和黄医药计划于2026年上半年重新提交索乐匹尼布用于二线治疗免疫性血小板减少症的新药上市申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109073817a7049eb3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109073817a7049eb3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1588","00013","BK1587"],"gpt_icon":0},{"id":"2602960063","title":"每日卖空追踪 | 和黄医药 01月08日卖空量成交29.05万股，卖空比例为3.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602960063","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602960063?lang=zh_cn&edition=full","pubTime":"2026-01-08 16:30","pubTimestamp":1767861009,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月08日，涨3.47%，卖空量成交29.05万股，较上一交易日减少50.09%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164238a7023720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108164238a7023720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","00013","BK1587","BK1191"],"gpt_icon":0},{"id":"2601808383","title":"港股概念追踪|国家药监局优化临床急需境外已上市药品审评审批    创新药高景气度延续（附概念股）","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808383","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601808383?lang=zh_cn&edition=full","pubTime":"2026-01-08 08:07","pubTimestamp":1767830855,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，记者从国家药监局获悉，为加快临床急需境外已上市药品在境内上市，满足患者临床用药迫切需求，国家药监局进一步优化这类药品审评审批。公告显示，国家药监局将优化审评机制，加快审评速度;同时，也将完善检验制度，体现品种特点。据了解，2025年国家药监局批准上市的76个创新药，包括47个化学药品、23个生物制品和6个中药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"de4be8e90342c7505536e308e38cab46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0417516571.SGD","IE00B5MMRT66.SGD","LU1720050803.USD","LU2778985437.USD","159992","06978","LU0417516902.SGD","LU1794554557.SGD","BK1587","IE00B543WZ88.USD","LU0348784397.USD","LU2488822045.USD","BK1191","LU0348766576.USD","LU0540923850.HKD","BK1574","LU0634319403.HKD","LU2476274720.SGD","LU0561508036.HKD","BK1588","BK1161","LU0417516738.SGD","LU2476274308.USD","LU0348767384.USD","LU0348825331.USD","LU2399975544.HKD","09926","LU0348783233.USD","00013","LU0348827113.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU0348735423.USD"],"gpt_icon":0},{"id":"2601291804","title":"索乐匹尼布取得突破性进展！和黄医药股价涨5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601291804","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601291804?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:04","pubTimestamp":1767787448,"startTime":"0","endTime":"0","summary":"另值得关注的是，除了温抗体型自身免疫性溶血性贫血以外，索乐匹尼布治疗免疫性血小板减少症的研究亦正在进行中。和黄医药透露，公司计划于2026年上半年重新提交索乐匹尼布，用于二线治疗免疫性血小板减少症的新药上市申请。综合来看，索乐匹尼布具有不错的商业化前景，后续若其在温抗体型自身免疫性溶血性贫血、免疫性血小板减少症两大适应症的新药上市申请获成功，将有望为公司业绩增长贡献助力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107200638a6fead82&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107200638a6fead82&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","HCM","BK4585","BK4588","BK4531","00013"],"gpt_icon":0},{"id":"2601385110","title":"每日卖空追踪 | 和黄医药 01月07日卖空量成交28.95万股，卖空比例为1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601385110","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601385110?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:30","pubTimestamp":1767774608,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月07日，涨5.45%，卖空量成交28.95万股，较上一交易日减少29.48%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163022a4a6e13c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107163022a4a6e13c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","BK1191","00013","BK1587"],"gpt_icon":0},{"id":"2601385111","title":"和黄医药01月07日获主力加仓644.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601385111","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601385111?lang=zh_cn&edition=full","pubTime":"2026-01-07 16:15","pubTimestamp":1767773755,"startTime":"0","endTime":"0","summary":"01月07日, 和黄医药股价涨5.45%，报收22.46元，成交金额3.4亿元，换手率1.77%，振幅5.54%，量比3.15。和黄医药今日主力资金净流入644.9万元，上一交易日主力净流入228.1万元。该股近5个交易日上涨9.78%，主力资金累计净流入60.4万元；近20日主力资金累计净流入444.0万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107162205a6fdce88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107162205a6fdce88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","00013","BK1191","BK1587"],"gpt_icon":0},{"id":"2601760808","title":"港股创新药ETF基金涨近3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601760808","media":"云掌财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601760808?lang=zh_cn&edition=full","pubTime":"2026-01-07 13:58","pubTimestamp":1767765495,"startTime":"0","endTime":"0","summary":"盘面上，港股创新药表现活跃，凯莱英飙涨7%，泰格医药、昭衍新药、康方生物涨超5%，和黄医药、翰森制药、恒瑞医药等个股涨超4%。截至10：34，热门ETF——港股创新药ETF基金上涨2.85%，冲击三连涨！数据显示，港股创新药ETF基金近60日“吸金”超1亿；最新基金规模达9.39亿元。港股创新药ETF基金跟踪中证港股通创新药指数，指数编制方式更科学合理，成分股涵盖如百济神州、信达生物和药明生物等领军企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107135820a4a649a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03692","01276","06127","06978","09926","BK1161","06821","01801","02315","BK1574","02269","00013","BK1191"],"gpt_icon":0},{"id":"2601878841","title":"和黄医药(00013)宣布索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的 ESLIM-02中国研究的III期阶段取得阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2601878841","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601878841?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:03","pubTimestamp":1767744211,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，新型脾酪氨酸激酶抑制剂索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血成人患者的ESLIM-02研究的III期注册阶段已达到第5至 24周治疗期间持久血红蛋白应答这一主要终点。ESLIM-02研究的完整数据将提交于近期的学术会议上发表。和黄医药计划于2026年上半年向中国国家药品监督管理局提交索乐匹尼布用于治疗温抗体型自身免疫性溶血性贫血的新药上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1389595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK4531","BK4588","BK1191","III","BK4585","00013","BK4007","BK1587","HCM","BK1588"],"gpt_icon":0},{"id":"1133162893","title":"和黄医药公布索乐普尼治疗温抗体自身免疫性溶血性贫血中国III期ESLIM-02试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133162893","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133162893?lang=zh_cn&edition=full","pubTime":"2026-01-07 08:00","pubTimestamp":1767744014,"startTime":"0","endTime":"0","summary":"和黄医药今日宣布，其创新药物索乐普尼针对温抗体自身免疫性溶血性贫血在中国开展的ESLIM-02试验III期阶段取得积极的顶线结果。\n该研究达到了预设的主要疗效终点，数据显示索乐普尼治疗组在关键指标上表现出具有统计学显著性和临床意义的改善。安全性方面，索乐普尼的表现与既往研究数据一致，未发现新的安全性信号。\n这一积极成果标志着索乐普尼在治疗这一罕见血液疾病方面迈出了关键一步，为后续向监管机构提交上市申请奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","00013","BK1587","BK1588"],"gpt_icon":0},{"id":"2601929998","title":"每日卖空追踪 | 和黄医药 01月06日卖空量成交20.65万股，卖空比例为4.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601929998","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601929998?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:30","pubTimestamp":1767688207,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月06日，涨0.57%，卖空量成交20.65万股，较上一交易日减少72.36%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163021a6f97f0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106163021a6f97f0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","00013","BK1587","BK1191"],"gpt_icon":0},{"id":"2601289299","title":"和黄医药01月06日主力净流入228.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2601289299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601289299?lang=zh_cn&edition=full","pubTime":"2026-01-06 16:15","pubTimestamp":1767687339,"startTime":"0","endTime":"0","summary":"01月06日, 和黄医药股价涨0.57%，报收21.30元，成交金额9349.2万元，换手率0.51%，振幅2.36%，量比0.95。和黄医药今日主力资金净流入228.1万元，上一交易日主力净流出13.5万元。该股近5个交易日上涨3.41%，主力资金累计净流出11.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出757.6万元，其中净流出天数为12日。该股主力净额占比0.01%，港股市场排名387/2708。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106161917a4a277aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106161917a4a277aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1191","BK1588","BK1587"],"gpt_icon":0},{"id":"2601868644","title":"中信建投：脑机接口有望打开万亿市场空间 需发掘国家政策支持和具有真实需求“真脑机”","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868644","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601868644?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:27","pubTimestamp":1767670058,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投发布研报称，脑机接口升级为十五五产业战略，多重政策强力支持下，产业落地有望提速，建议重视投资机遇。脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来看若能实现增强人、并与AI和机器人融合，有望打开万亿市场空间。在投资方向选择方面，非侵入式和侵入式脑机接口无优劣之分，但需发掘国家政策支持和具有真实需求的“真脑机”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106113407a6f87063&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1046422090.SGD","09926","LU2242644610.SGD","BK1576","BK1583","SHPMY","LU0320764599.SGD","01801","06160","02359","01177","LU0052750758.USD","BK1141","LU2045819591.USD","BK1161","LU0708995583.HKD","03347","02607","06978","LU2125910500.SGD","00013","01099","BK1574","02269"],"gpt_icon":0},{"id":"2601189294","title":"科伦博泰ITGB6靶向ADC癌症新药获批临床|复宏汉霖三款创新药IND同期获受理|和黄医药赛沃替尼申报上市并获纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2601189294","media":"中国医药创新促...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601189294?lang=zh_cn&edition=full","pubTime":"2026-01-06 11:24","pubTimestamp":1767669859,"startTime":"0","endTime":"0","summary":"12月30日，和黄医药宣布，赛沃替尼用于经过至少2种治疗后失败的MET基因扩增的局部晚期或转移性胃癌或胃食道连接部腺癌成人患者的新药上市申请已获中国国家药品监督管理局受理，并获纳入优先审评。以上三款产品皆拟用于实体肿瘤的治疗。科伦博泰 注射用SKB1051月4日，中国国家药监局药品审评中心官网最新公示，科伦博泰申报的1类新药注射用SKB105获批临床，拟开发治疗晚期实体瘤。公开资料显示，这是一款靶向整合素β6的抗体偶联药物。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106121530a4a199b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106121530a4a199b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","HK0000165453.HKD","06978","00013","BK1161","BK1191","BK1574","BK1588","02696"],"gpt_icon":0},{"id":"2601854186","title":"千亿出海潮：中国创新药企驶入全球深水区","url":"https://stock-news.laohu8.com/highlight/detail?id=2601854186","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601854186?lang=zh_cn&edition=full","pubTime":"2026-01-06 07:13","pubTimestamp":1767654792,"startTime":"0","endTime":"0","summary":"中国药企不仅成为全球医药研发体系中不可忽视的力量，也在重新定义自身在国际市场上的角色。从首付款到里程碑款的持续流入，标志着中国创新药的全球开发已实质性推进至临床中后期乃至商业化阶段。这意味着中国药企不再只是技术提供方，而是以平等伙伴身份参与全球价值创造与分配。中国药企在跨境谈判、知识产权布局、国际争议解决等方面经验仍显不足。锻造出海“航母舰队”中国创新药的集体出海，离不开产业集群的支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106071431a6f7878c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4585","06160","00013","BK4139","ONC","CXO","02509","BMS","01801","01167","01541"],"gpt_icon":0},{"id":"2601078362","title":"和黄医药(00013)启动现正进行中的索凡替尼联合卡瑞利珠单抗用于治疗初治胰腺导管腺癌研究的III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2601078362","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601078362?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:09","pubTimestamp":1767571757,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和黄医药 公布，公司今日宣布启动索凡替尼联合卡瑞利珠单抗、白蛋白结合型紫杉醇和吉西他滨用于一线治疗转移性胰腺导管腺癌患者的中国II/III期研究的III期部分。首名患者已于2025年12月30日接受首次给药治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HCM","00013","BK1588","III","BK1587","BK4585","BK4531","BK1191","BK4134","BK4588","BK4007"],"gpt_icon":1},{"id":"1179815875","title":"和黄医药启动索凡替尼联合卡瑞利珠单抗治疗初治胰腺导管腺癌的III期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1179815875","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179815875?lang=zh_cn&edition=full","pubTime":"2026-01-05 08:03","pubTimestamp":1767571413,"startTime":"0","endTime":"0","summary":"和黄医药（HUTCHMED）已正式启动其正在进行的索凡替尼（surufatinib）与卡瑞利珠单抗（camrelizumab）联合疗法针对初治胰腺导管腺癌（PDAC）患者的III期临床试验阶段。\n该研究旨在评估这一组合疗法在未曾接受过系统性治疗的胰腺导管腺癌患者中的疗效与安全性。胰腺导管腺癌作为一种恶性程度高、预后极差的消化道肿瘤，目前临床治疗选择有限，患者生存率普遍较低。\n和黄医药此次推进至III期研究，标志着该联合疗法在前期临床试验中展现出潜在的应用前景。若III期试验结果积极，有望为胰腺导管腺癌患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1191","BK1587","00013"],"gpt_icon":0},{"id":"1116195581","title":"和黄医药（中国）（00013）公布2025年12月股份变动月报，共增发157,950股","url":"https://stock-news.laohu8.com/highlight/detail?id=1116195581","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116195581?lang=zh_cn&edition=full","pubTime":"2026-01-02 17:01","pubTimestamp":1767344505,"startTime":"0","endTime":"0","summary":"和黄医药（中国）有限公司于2026年1月2日发布截至2025年12月31日的股份变动月报。报告期内，公司注册股本维持在15亿股普通股，对应注册股本总额1.5亿美元，无变动。本月已发行股份由上月底的872,169,670股增至872,327,620股，新增157,950股，主要来自公司于2015年4月24日采纳的认股权计划中股份期权的行使。根据公告披露，此次期权行使所获资金总额为348,568.5美元。本次公告由非执行董事兼公司秘书施熙德签署，现有股本结构于2025年12月31日保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00013"],"gpt_icon":0},{"id":"2600097256","title":"每日卖空追踪 | 和黄医药 01月02日卖空量成交5.15万股，卖空比例为2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600097256","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600097256?lang=zh_cn&edition=full","pubTime":"2026-01-02 16:30","pubTimestamp":1767342608,"startTime":"0","endTime":"0","summary":"和黄医药北京时间01月02日，涨1.55%，卖空量成交5.15万股，较上一交易日减少90.56%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163016a6eb278f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260102163016a6eb278f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00013","BK1191","BK1588","BK1587"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hutch-med.com","stockEarnings":[{"period":"1week","weight":0.1098},{"period":"1month","weight":0.085},{"period":"3month","weight":-0.0606},{"period":"6month","weight":-0.0904},{"period":"1year","weight":-0.0456},{"period":"ytd","weight":0.1271}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和黄医药（中国）有限公司是一间主要从事制造及销售药物的投资控股公司。该公司主要通过两个分部运营业务。肿瘤免疫业务分部从事发现、开发和商业化用于治疗癌症和免疫性疾病的靶向疗法和免疫疗法。其中研发包括涵盖药物发现、开发、生产及监管职能的研发活动，上市产品包括通过研发活动开发的药物的已开具发票的销售、推广、生产及分销。其他业务分部从事其他商业化业务，包括其他处方药物及保健品的销售、推广、生产及分销。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.067746},{"month":2,"riseRate":0.75,"avgChangeRate":0.102065},{"month":3,"riseRate":0.25,"avgChangeRate":-0.11719},{"month":4,"riseRate":0.5,"avgChangeRate":0.030514},{"month":5,"riseRate":0,"avgChangeRate":-0.153959},{"month":6,"riseRate":0.5,"avgChangeRate":0.026468},{"month":7,"riseRate":1,"avgChangeRate":0.148281},{"month":8,"riseRate":0.2,"avgChangeRate":-0.0763},{"month":9,"riseRate":0.6,"avgChangeRate":-0.004654},{"month":10,"riseRate":0.2,"avgChangeRate":-0.040611},{"month":11,"riseRate":0.4,"avgChangeRate":0.13917},{"month":12,"riseRate":0.4,"avgChangeRate":-0.030017}],"exchange":"SEHK","name":"和黄医药","nameEN":"HUTCHMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和黄医药,00013,和黄医药股票,和黄医药股票老虎,和黄医药股票老虎国际,和黄医药行情,和黄医药股票行情,和黄医药股价,和黄医药股市,和黄医药股票价格,和黄医药股票交易,和黄医药股票购买,和黄医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和黄医药(00013)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和黄医药(00013)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}